Clinical Cancer Research Landon Prizes for Basic and Translational Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Itoh, M.
Right arrow Articles by Okazaki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Itoh, M.
Right arrow Articles by Okazaki, T.
Clinical Cancer Research Vol. 9, 415-423, January 2003
© 2003 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Possible Role of Ceramide as an Indicator of Chemoresistance

Decrease of the Ceramide Content via Activation of Glucosylceramide Synthase and Sphingomyelin Synthase in Chemoresistant Leukemia1

Mitsuru Itoh, Toshiyuki Kitano, Mitsumasa Watanabe, Tadakazu Kondo, Takeshi Yabu, Yoshimitu Taguchi, Kazuya Iwai, Masaro Tashima, Takashi Uchiyama and Toshiro Okazaki2

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507 [M. I., T. Ki., M. W., T. Ko., T. Y., Y. T., K. I., M. T., T. U., T. O.], and Laboratory of Membrane Biochemistry and Biophysics, Graduate School of Biostudies, Kyoto University, Kyoto 606-8501 [Y. T.], Japan

We investigated the possibility of the proapoptotic lipid ceramide as an indicator of chemoresistance in leukemia. Doxorubicin (DOX) increased the ceramide level and apoptosis in drug-sensitive HL-60 cells but not in drug-resistant HL-60/ADR cells, under the condition that the uptake of DOX was not different between the two cell lines. In addition, exogenous N-acetylsphingosine (C2-ceramide) enhanced DOX-induced apoptosis in HL-60/ADR cells without affecting the expression of multidrug resistant-1 protein (MDR 1) and the uptake of DOX. A lower level of ceramide with higher activities of glucosylceramide synthase (GCS) and sphingomyelin synthase (SMS) was detected in HL-60/ADR cells than in HL-60 cells. In contrast, HL-60/GCS cells, overexpressing GCS, significantly inhibited DOX-induced ceramide increase and apoptosis. These observations suggest the involvement of ceramide regulation in drug resistance of leukemia cells. In vivo, the level of ceramide was lower in chemoresistant leukemia patients (6.4 ± 1.8 pmol/nmol phosphate; n = 14) than in chemosensitive patients (9.5 ± 2.7 pmol/nmol phosphate; n = 9), and the activities of GCS and SMS were more than 2-fold higher in chemoresistant leukemia cells than in chemosensitive cells. MDR-1 protein was faintly expressed in one of four chemoresistant patients, but Bcl-2 were clearly detected in four patients. Therefore, it is suggested that a decrease of the ceramide level via activation of GCS and SMS is associated with the chemoresistant condition in leukemia, probably in relation to Bcl-2 but not to MDR-1 expression.




This article has been cited by other articles:


Home page
FASEB J.Home page
Y.-Y. Liu, J. Y. Yu, D. Yin, G. A. Patwardhan, V. Gupta, Y. Hirabayashi, W. M. Holleran, A. E. Giuliano, S. M. Jazwinski, V. Gouaze-Andersson, et al.
A role for ceramide in driving cancer cell resistance to doxorubicin
FASEB J, July 1, 2008; 22(7): 2541 - 2551.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Charruyer, S. M. Bell, M. Kawano, S. Douangpanya, T.-Y. Yen, B. A. Macher, K. Kumagai, K. Hanada, W. M. Holleran, and Y. Uchida
Decreased Ceramide Transport Protein (CERT) Function Alters Sphingomyelin Production following UVB Irradiation
J. Biol. Chem., June 13, 2008; 283(24): 16682 - 16692.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. G. Tafesse, K. Huitema, M. Hermansson, S. van der Poel, J. van den Dikkenberg, A. Uphoff, P. Somerharju, and J. C. M. Holthuis
Both Sphingomyelin Synthases SMS1 and SMS2 Are Required for Sphingomyelin Homeostasis and Growth in Human HeLa Cells
J. Biol. Chem., June 15, 2007; 282(24): 17537 - 17547.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. E. van Vlerken, Z. Duan, M. V. Seiden, and M. M. Amiji
Modulation of Intracellular Ceramide Using Polymeric Nanoparticles to Overcome Multidrug Resistance in Cancer
Cancer Res., May 15, 2007; 67(10): 4843 - 4850.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
M. Noguchi, K. Kabayama, S. Uemura, B.-w. Kang, M. Saito, Y. Igarashi, and J.-i. Inokuchi
Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells
Glycobiology, July 1, 2006; 16(7): 641 - 650.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Holleman, M. L. den Boer, R. X. de Menezes, M. H. Cheok, C. Cheng, K. M. Kazemier, G. E. Janka-Schaub, U. Gobel, U. B. Graubner, W. E. Evans, et al.
The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia
Blood, January 15, 2006; 107(2): 769 - 776.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Pchejetski, M. Golzio, E. Bonhoure, C. Calvet, N. Doumerc, V. Garcia, C. Mazerolles, P. Rischmann, J. Teissie, B. Malavaud, et al.
Sphingosine Kinase-1 as a Chemotherapy Sensor in Prostate Adenocarcinoma Cell and Mouse Models
Cancer Res., December 15, 2005; 65(24): 11667 - 11675.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Taguchi, T. Kondo, M. Watanabe, M. Miyaji, H. Umehara, Y. Kozutsumi, and T. Okazaki
Interleukin-2-induced survival of natural killer (NK) cells involving phosphatidylinositol-3 kinase-dependent reduction of ceramide through acid sphingomyelinase, sphingomyelin synthase, and glucosylceramide synthase
Blood, November 15, 2004; 104(10): 3285 - 3293.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Mahadevan and A. F. List
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
Blood, October 1, 2004; 104(7): 1940 - 1951.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Uchida, M. Itoh, Y. Taguchi, S. Yamaoka, H. Umehara, S.-i. Ichikawa, Y. Hirabayashi, W. M. Holleran, and T. Okazaki
Ceramide Reduction and Transcriptional Up-Regulation of Glucosylceramide Synthase through Doxorubicin-Activated Sp1 in Drug-Resistant HL-60/ADR Cells
Cancer Res., September 1, 2004; 64(17): 6271 - 6279.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Yamaoka, M. Miyaji, T. Kitano, H. Umehara, and T. Okazaki
Expression Cloning of a Human cDNA Restoring Sphingomyelin Synthesis and Cell Growth in Sphingomyelin Synthase-defective Lymphoid Cells
J. Biol. Chem., April 30, 2004; 279(18): 18688 - 18693.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Holleman, M. L. d. Boer, K. M. Kazemier, G. E. Janka-Schaub, and R. Pieters
Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia
Blood, December 15, 2003; 102(13): 4541 - 4546.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.